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Objective: This study evaluated the safety and effectiveness of the Zenith Dissection Endovascular System (Cook Medical,
Bloomington, Ind) in the urgent treatment of acute type B aortic dissections complicated by organ malperfusion.
Methods: Between June 2011 and June 2013, we prospectively enrolled all patients with acute type B dissection (<14 days)
complicated by visceral malperfusion and treated by the Zenith Dissection Endovascular System, including a proximal
covered stent and a distal noncovered stent. Organ malperfusion was diagnosed during the clinical, biological, and
morphologic follow-up of patients admitted to a dedicated intensive care unit (SOS Aorta). End points were 30-day
mortality and morbidity, and reoperation rate, survival, and remodelling of the dissected aorta during follow-up.
Results: Fifteen patients (11 men; mean age, 60 6 12 years) were treated in emergency procedures with a median delay of
36 hours. Malperfusions included renal ischemia in all patients, intestinal ischemia in nine, and lower limb ischemia in six.
The proximal entry tear in each patient was covered by a stent Zenith TX2 graft (mean diameter, 36 mm; mean length,
170 mm; Cook Medical), supplemented by a noncovered aortic stent (diameter, 36 or 46 mm; length, 164 mm) with
a technical success rate of 100%. The left subclavian artery in 10 patients was covered without revascularization. One
chimney was necessary to revascularize the left common carotid artery. Six patients required complementary arterial
branch stenting for persistent static malperfusion, using eight peripheral stents (ﬁve iliacs, three renals). No deaths were
recorded during the 30-day postoperative period. Major adverse events were reported in three patients (20%): 1 para-
paresis with complete recovery, 1 colonic resection, 1 stroke, and 2 transient renal failures. The mean hospital stay was
14 6 6 days. During a mean follow-up of 8 6 3 months, one sudden death, no aortic-related complications, and no
reoperations or conversions were recorded. Remodelling with healing of the thoracic false lumen was obtained in
10 patients (67%), and ﬁve others had a partially thrombosed false lumen without remodelling.
Conclusions: Used as a treatment for organ malperfusion complicating acute type B dissections, the Zenith Dissection
Endovascular System achieved safely and effectively satisfactory clinical results in the short term. The long-term effect of
this composite treatment on aortic remodelling remains to be determined. (J Vasc Surg 2014;59:645-50.)Malperfusion of the visceral arteries is one of the most
challenging complications of acute aortic dissection
because it can be fatal in the short term.1 Malperfusion is
most often associated with a higher pressure in the false
lumen of the dissected aorta, which leads to a “dynamic”
compression of the true lumen where most collaterals for
the visceral arteries arise.2 The treatments currently avail-
able for these malperfusions attempt therefore by endovas-
cular means to relieve this dynamic compression by closing
the main entry tear of the dissection using a stent graft
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://dx.doi.org/10.1016/j.jvs.2013.09.004tear by a distal retrograde fenestration.4 To promote the
true lumen expansion and perfusion vs the false lumen
pressure, the Zenith Dissection Endovascular System
(Cook Medical, Bloomington, Ind) proposes a composite
device with noncovered metal stents that extends into the
thoracoabdominal aorta, below the proximal thoracic
aortic stent graft.5,6
The purpose of our study was to assess the safety and
effectiveness of the Zenith Dissection Endovascular System
in the urgent treatment of acute type B aortic dissections
complicated by organ malperfusions.
METHODS
Between June 2011 and June 2013, we prospectively
enrolled 52 patients with acute type B dissection
(<14 days) in our dedicated database for aortic emergen-
cies. All of these patients were managed according to
a speciﬁc aortic protocol of care (SOS Aorta), in a dedicated
intensive care unit, by a surgical team including cardiac,
vascular, and endovascular specialists. The diagnosis of
Stanford type B aortic dissection was made on a computed
tomography (CT) scan <14 days before admission and
within 14 days from the initial onset of symptoms. Clinical645
Fig 1. The Zenith Dissection Endovascular System consists of two
modular components: the Zenith TX2 Dissection Endovascular
Graft with Pro-Form (same as the proximal component of the two-
piece TX2 device for the treatment of thoracic aneurysms without
proximal hooks) and the Zenith Dissection Endovascular Stent.
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of arterial blood pressure. Biological surveillance included
a daily serum creatinine and lactate monitoring. Systematic
control CT scans were performed between 48 and 72 hours
after admission and before discharge. Among these 52
patients, 25 (58%) were treated with aortic stent grafts
for acute complications.
During this close clinical, biological, and morphologic
surveillance, 15 patients were diagnosed with organ mal-
perfusion and were treated by the Zenith Dissection Endo-
vascular System. An additional 10 patients were treated
during the study period with covered stent grafts alone
for other complications such as rupture, expanding aorta,
or uncontrolled chest pain.
As reported by White et al,7 malperfusion in the setting
of an aortic dissection was deﬁned as one or more of the
following:
1. Viscera hypoperfusion by an acute abdomen, abdom-
inal pain out of proportion to physical examination
ﬁndings in setting of radiographic hypoperfusion of
mesenteric bed, lactic acidosis attributed to visceral
malperfusion, or need for bowel resection;
2. Renal hypoperfusion, including oliguria or aneuria in
the setting of rising renal function tests (creatinine or
blood urea nitrogen) or radiographic evidence of
impaired renal artery blood ﬂow;
3. Lower extremity hypoperfusion indicated by
abnormal pulse examinations in conjunction with
leg pain, pallor, paresthesias, or paralysis;
4. Spinal cord hypoperfusion as noted by altered motor
function of one or both of legs attributed to a possible
spinal cord source.
The Zenith Dissection Endovascular System com-
prises two modular components: the Zenith TX2 Dissec-
tion Endovascular Graft with Pro-Form (same as the
proximal component of the two-piece TX2 device for
the treatment of thoracic aneurysms without proximal
hooks)8 and the Zenith Dissection Endovascular Stent
(Fig 1). Preoperative multiplanar CT scan reconstruc-
tions using Vascular 4.2 software (3mensio Medical
Imaging BV, Bilthoven, The Netherlands) was used for
selecting the proximal and distal landing zones and for
device sizing. Generally, up to 10% oversizing of the stent
graft based on the proximal landing zone diameter was
recommended.
After deployment of the TX2 stent graft component
to cover the primary entry tear, deployment of the bare
stent component was performed systematically in the thor-
acoabdominal aorta to the level of the visceral arteries.
The decision to extend the distal bare stent under the
visceral and renal arteries ostia was based on the distal
extension of the dissection to the aortic bifurcation level.
Because two diameters of the bare stent component were
available (36 mm and 46 mm), the size was chosen accord-
ing to the diameter of the proximal covered stent graft.
A diameter of 36 mm was chosen for proximal stentgrafts <36 mm, and a diameter of 46 mm was chosen to
extend stent grafts >36 mm.
Molding balloon angioplasty within the TX2 stent graft
and the bare dissection stent was optional. Adjunctive stent
placement for remaining obstructed branch vessels was per-
formed as necessary, at the discretion of the operating
physician, based on completion angiogram results at the
level of visceral and iliac arteries.
Morphologic follow-up consisted of a control CT scan
before discharge, at 1 and 6 months, and yearly thereafter.
A close clinical examination was associated during the
hospital stay and by control visits at 1 and 6 months and
yearly thereafter.
Analyzed outcomes were 30-day mortality and
morbidity, reoperation, survival, and remodeling rates of
the dissected aorta during follow-up. Remodeling was
deﬁned by complete thrombosis and retraction of the false
lumen diameter, with an expansion of the true lumen
diameter.9RESULTS
Fifteen patients (11 men; mean age, 61 6 12 years)
were treated in emergency procedures with a median delay
of 36 hours (range, 4 hours-8 days) after admission for
acute type B dissection complicated by malperfusion. The
mean time from symptom onset to treatment was 6 days
(range, 4 hours-12 days). Patient characteristics and preop-
erative conditions are presented in Table I. All Stanford
type B acute dissections involved the thoracoabdominal
aorta, with the most proximal tear in the thoracic aorta
Table I. Patient characteristics, preoperative conditions,
and risk assessment
Preoperative conditions % No. (N ¼ 15)
Coronary artery disease with previous MI 6.7 1
Peripheral vascular disease 6.7 1
Hypertension 93.3 14
Chronic obstructive pulmonary disease 26.7 4
Chronic renal failure without dialysis 13.3 2
Diabetes 13.3 2
Smoker 46.7 7
Hyperlipidemia 33.3 5
MI, Myocardial infarction.
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arteries.
Patients’ indications, based on organ malperfusion, and
procedure details are reported in Table II. Malperfusions
included renal ischemia in all 15 patients, intestinal
ischemia in 9, lower limb ischemia in 6, and spinal cord
ischemia in 1 (paraparesis).
All procedures were performed under general anes-
thesia and through femoral accesses. For each patient, the
proximal entry tear was covered by one Zenith TX2 Dissec-
tion with a Pro-Form straight stent graft with a mean diam-
eter of 36 mm (range, 32-42 mm) and a mean length of
170 mm (range, 140-202 mm). An additional proximal
extension (diameter, 36-42 mm; length, 77-81 mm) was
used in three patients to ensure correct proximal sealing
of the proximal entry tear. Afterward, the noncovered
Zenith Dissection Endovascular Stent was distally
implanted in the thoracoabdominal aorta, with one to
three stents of overlap into the proximal TX2 stent graft
and with a diameter of 36 or 46 mm and a length of
164 mm. The technical success rate was 100%, and the
proximal entry tear was sealed in all patients.
The left subclavian artery was covered without revascu-
larization in 10 patients, and one chimney was necessary to
revascularize the left common carotid artery in one patient.
Six patients required complementary arterial branches
stenting for persistent static malperfusion, using eight
peripheral stents (ﬁve iliacs, three renals). In two cases of
renal stenting, the nitinol bare stent was successfully
deployed across the mesh of the Zenith Dissection Endo-
vascular Stent (Fig 2). All visceral branches were patent
after the ﬁrst treatment, and no reintervention was neces-
sary for remaining malperfusion. All procedures were per-
formed using endovascular means, and no extra-anatomic
bypass was necessary for branch revascularization.
Mean procedure time (from incision to closure) was
116 minutes (range, 43-243 minutes). Mean radiation
dose was 6.3 6 4.7 mGym2, and mean contrast media
was 143 6 45 mL.
Median intensive care unit stay was 4 days (range,
0-13 days), and overall hospital length of stay was 14 days
(range, 7-18 days).
No deaths were recorded during the 30-day postoper-
ative period. Five major adverse events were reported inthree patients (20%): 1 regressive paraparesis, 1 colonic
resection, 1 stroke, and 2 transient renal failures requiring
temporary dialysis. Concerning the patient who presented
with spinal cord ischemia, the left subclavian artery was
left patent by the proximal Zenith TX2 Dissection Stent
graft, and adjunctive cerebrospinal ﬂuid drainage was per-
formed for 4 days after the procedure. This patient had
fully recovered from paraparesis at his 1-month visit.
During a mean follow-up of 8 6 3 months, one pa-
tient died suddenly at home 51 days after the procedure
of unknown reasons (no autopsy was done). Postproce-
dural CT scans showed patent and intact devices, a throm-
bosed thoracic false lumen, and a patent abdominal false
lumen perfused by collateral ﬂow. The clinical examination
at discharge (at 12 days) did not show pain, discomfort, or
other symptoms. In this patient, aortic rupture cannot be
excluded.
No other aortic-related complication, reoperation, or
conversion to open repair was recorded. No retrograde
extension of the dissection and no type I endoleak at the
level of the proximal tear was reported on control CT
scans. All visceral branches remained patent on control
CT scans, and no reintervention was necessary for recur-
rent malperfusion. Remodeling with healing of the thoracic
false lumen was obtained in 10 patients (71%) with
a complete thrombosis of the false lumen. Four others
had a partially thrombosed false lumen without remodeling
or expansion of the aorta.
DISCUSSION
This study reports the largest monocentric experience
with using the Zenith Dissection Endovascular System in
the urgent treatment of acute type B aortic dissections
complicated by organ malperfusions. In our growing expe-
rience with the management of acute aortic dissections, the
Zenith Dissection Endovascular System achieved safe and
effective clinical results in the short term in patients with
dynamic organ malperfusion. Associated with primary
entry tear occlusion by a thoracic aortic stent graft, the
addition of a noncovered stent exerting a radial force on
the dissected wall of true lumen demonstrated an imme-
diate increase in the true lumen diameter. This composite
technique of aortic stent grafting was safe, efﬁcient, and
reproducible, for improving perfusion of the abdominal
branches arising from the true lumen.
Static obstruction of aortic branch vessels can persist
despite depressurization of the false lumen and elimination
of dynamic obstruction because of extension of the false
lumen into branch vessel ostia.10 As was shown in two
patients, the placement of the Zenith Dissection Endovas-
cular Stent also facilitated subsequent spot stenting of
“statically” malperfused renal branches. The expansion of
the true lumen allows realignment of the intimal ostia of
dissected branches. The open design of the mesh of the
Zenith Dissection Endovascular Stent allowed relatively
easy access and cannulation of the malperfused renal
branches, bridging the true lumen and target vessels with
a self-expending stent. To obtain a complete thrombosis
Table II. Patient indications on malperfused organs (vessels) and procedure details
Pt Malperfused organ (vessel) Stent graft, No.
Diameter/length, mm
LSA covered Other proceduresStent graft Stent
1 Mesenteric (SMA) 1 TX2a 38/152 46/164 Yes No
Left kidney
2 Mesenteric (CT þ SMA) 1 TX2 34/152 36/164 No Left renal stenting
Kidneys
Left LL
3 Mesenteric (SMA) 2 TX2 36/77 þ 152 36/164 Yes LCCA chimney
Right kidney
Right LL
4 Left kidney 1 TX2 32/140 36/164 No No
5 Mesenteric (SMA) 1 TX2 40/162 46/164 No No
Kidneys
6 Left kidney 1 TX2 34/202 36/164 Yes No
7 Mesenteric (CT þ SMA) 2TX2 40/81 þ 162 46/164 Yes RCIA stent
Left kidney
Bilateral LL
8 Left kidney 1 TX2 32/200 36/164 Yes LCIA stent
Left LL
9 Mesenteric (CT þ SMA) 2 TX2 42/81 þ 162 46/164 Yes Right renal stent
Kidneys
10 Left kidney 1 TX2 36/202 36/164 Yes CIA kissing stent
Bilateral LL
11 Spinal cord left kidney 1 TX2 34/152 36/164 No Cerebrospinal ﬂuid drainage
for 4 post-op days
12 Mesenteric (CT þ SMA) 1 TX2 36/202 36/164 Yes No
Kidneys
13 Left kidney 1 TX2 36/202 36/164 Yes No
14 Mesenteric (CT þ SMA) 1 TX2 38/152 46/164 No Left renal stent
Kidneys RCIA stent
Right LL
15 Mesenteric (SMA) 1 TX2 34/152 36/164 Yes No
Kidneys
CT, Celiac trunk; LCCA, left common carotid artery, LCIA, left common iliac artery; LL, lower limb; LSA, left subclavian artery; RCIA, right common iliac
artery; SMA, superior mesenteric artery.
aZenith TX2 Dissection Endovascular Graft with Pro-Form, Cook Medical, Indianapolis, Ind.
JOURNAL OF VASCULAR SURGERY
648 Alsac et al March 2014of the false lumen, this bridge can be performed with
a covered stent graft that seals a distal entry tear, as we
recently described in a technical note.11
Six patients required additional stenting of arterial
branches. This high rate of complementary arterial
branch stenting is certainly because our series focused
on the speciﬁc indication of acute type B dissection
with organ malperfusions. All of our patients presented
with organ malperfusion, and this selection criterion
might have required more complementary arterial branch
stenting than other series using the Zenith Dissection
Endovascular System in mixed indications for endovascu-
lar treatment.
The absence of 30-day mortality in this series was
a signiﬁcantly better result than the mortality rates expected,
which are between 10% and 20% in contemporary studies
examining thoracic endovascular aortic repair (TEVAR)
for malperfusion caused by type B dissection.7,12,13 This
difference can be explained by the limited number of
patients in our series and by the global low mortality rate ob-
tained by our SOS Aorta program, with short delays of
admission and dedicated medical management.During the same 2-year period, 52 patients were
admitted for type B aortic dissection in our program, and
their 30-day mortality rate was 4% because of two aortic
ruptures. In this series, 25 patients (48%) were treated by
TEVAR in the acute phase for a complicated aortic dissec-
tion despite optimal medical treatment. This high ratio of
complicated dissections enrolled in our program can be
explained by the fact that most of our patients are referred
by primary care centers that may have selected them for
referral because of their complicated presentation.
Another reason could be that our close clinical, biolog-
ical, and morphologic surveillance program of acute type B
dissections might result in a more sensitive diagnosis of
complicated cases, such as renal malperfusion alone with
resistant hypertension or rapid aortic enlargement. It is
possible that our patients were supported earlier in the
acute phase of the disease and also that our attitude was
more interventional due to this very close monitoring.
Therefore, an intervention performed as soon as possible,
indicated on the very early signs of malperfusion, ensures
a faster recovery of the ischemic organs, reduces the post-
operative risk of dialysis and bowel resection, and gives
Fig 2. A, An angiogram at the abdominal level after successful deployment of the Zenith Dissection Endovascular
system shows a persistent static malperfusion of the left renal artery. B, The left renal artery could be catheterized
through the open web of the Zenith Dissection Endovascular Stent. C, Completion angiogram after stenting of the left
renal artery deployed across the mesh of the Zenith Dissection Endovascular Stent.D, Postoperative control computed
tomography (CT) scan shows the good position of the renal stent without kinking.
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Owing to its reproducible and standardized character of
deployment, the Zenith Dissection Endovascular System
enabled our endovascular team to have the technical
capacity of dealing day or night with one of the most chal-
lenging endovascular procedures in the emergency settings
of acute aortic syndromes.
Despite these satisfactory immediate outcomes, ques-
tions remain about the long-term efﬁcacy of such
a composite device. Many recent studies seem to prove
the long-term beneﬁt of TEVAR in type B dissections
and especially when patients are treated in the acute phase.
Little is known about the potential long-term beneﬁt of
adding a bare stent in the thoracoabdominal aorta.
The prospective multicenter Staged Total Aortic and
Branch Vessel Endovascular Reconstruction (STABLE)study showed interesting ﬁrst-year results of aortic remod-
elling in 40 patients treated for acute and subacute dissec-
tions.6 But a comparative study between acute patients
treated with the Zenith TX2 Dissection Stent graft alone
or with the composite Zenith Dissection Endovascular
System is needed to prove the long-term beneﬁt of an addi-
tional aortic bare stent. In our experience, more than two-
thirds of the patients presented with a complete thrombosis
with aortic remodelling at the thoracic level in the midterm
course of their surveillance. The others had distal entry tear
in the abdominal aorta, ﬁlling backward a partially throm-
bosed false lumen.
To achieve false lumen elimination, a recent pub-
lication reports the Stent Assisted Balloon Induced Inti-
mal Disruption and Relamination in Aortic Dissection
Repair (STABILISE) technique.14 This technique intends
JOURNAL OF VASCULAR SURGERY
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the false lumen by a balloon expansion of the distal stent
graft and the bare dissection stent. Midterm results of
10 patients showed 90% of total obliteration of the thora-
coabdominal false lumen. If reproducible with safe results,
this technique could improve signiﬁcantly the long-term
course of aortic dissections. In our series, we observed
10 patients with remodeling with complete thrombosis of
the false lumen.
An additional beneﬁt provided by the noncovered stent
is difﬁcult to assess in this short and noncomparative study.
Furthermore, the effect of ballooning or not the distal non-
covered stent on distal sealing of the dissection was not
systematically evaluated. Only a larger series with longer
follow-up, comparing the aortic remodeling induced by
standard TEVAR with the TX2 Proform stent graft alone
vs the Zenith Dissection Endovascular System, could prove
an additional beneﬁt of one system over the other.
Our study presents many limitations because it is an
observational, prospective single-center study with a limited
number of patients and thus cannot draw ﬁrm evidence-
based conclusions about the efﬁciency of the Zenith Dis-
section Endovascular System. Furthermore, a comparative
study with patients presenting with acute type B dissection
complicated by organ malperfusion and treated by a prox-
imal stent graft alone could have been more powerful. But
fortunately, such patients are not so frequent, and the
design of such a study would require a long enrollment
from multiple centers. Because in our series this device
was revealed to be safe and particularly efﬁcient in speciﬁc
indications of acute type B dissection complicated by organ
malperfusion, we believe that this real-life experience
should be of interest for physicians managing such chal-
lenging acute aortic syndromes.
In addition, no quantiﬁcation of aortic remodeling was
performed because this series reports short-term results of
our experience with malperfusion complication. Long-
term results of a comparative study would be more appro-
priate to assess the beneﬁt of such a device on aortic
remodeling compared with conventional TEVAR alone.
CONCLUSIONS
Used as a systematic treatment for dynamic malperfu-
sion complicating acute type B dissections, the Zenith
Dissection Endovascular System safely and effectively
achieved satisfactory clinical results in the short term. The
long-term effect of this composite treatment on aortic
remodeling remains to be determined.
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